Liminal BioSciences reported an IFRS loss of C$11.164 million for the 3 months of 2022, down 46.5% from C$20.849 million in the previous year. The company did not generate revenue. A year earlier the figure was C$210 thousand.
Liminal BioSciences reported an IFRS loss of C$11.164 million for the 3 months of 2022, down 46.5% from C$20.849 million in the previous year. The company did not generate revenue. A year earlier the figure was C$210 thousand. 
English (US) 